Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.00
Bid: 41.00
Ask: 43.00
Change: 0.00 (0.00%)
Spread: 2.00 (4.878%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 42.00
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tarsis Collaboration with Crop-Protection Company

16 Jul 2018 07:00

RNS Number : 6299U
Frontier IP Group plc
16 July 2018
 

 

 

Released : 16 July 2018 07.00am

Frontier IP Group plc

16 July 2018

 

RNS REACH / RNS

AIM: FIPP

16 July 2018

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Tarsis Technology Collaboration with World-leading Crop-Protection Company

 

 

Frontier IP, which specialises in commercialising university intellectual property, is pleased to announce that portfolio company Tarsis Technology ("Tarsis"), a spin out from the University of Cambridge, has entered into a collaboration agreement with one of the world's leading manufacturers of crop-protection products (the "Company").

 

The collaboration will research the use of Tarsis' patent-pending technology to deliver chemical pesticides and fungicides in a more precise and controlled way.

 

Tarsis was incorporated to develop and commercialise technology created by Dr David Fairen-Jimenez, a Royal Society University Research Fellow and University Lecturer, and his research team at the Department of Chemical Engineering and Biotechnology at the University of Cambridge. The technology is based on particles called metal-organic frameworks and has potential for a wide range of industrial applications.

 

The Company will fund the entire research programme in return for exclusive rights to Tarsis' intellectual property for a defined set of agrochemicals. Tarsis will be paid a royalty fee for any commercially viable products that result.

 

Separately, Frontier IP has agreed to lend up to £150,000 to Tarsis to meet working capital requirements in return for equity options.

 

Tarsis Technology founder and director Dr David Fairen-Jimenez said: "We're delighted a leading player in global agrochemicals is happy to demonstrate such a strong commitment to our novel technology."

 

Frontier IP Chief Executive Neil Crabb said: "We aim to bring industry and university spin-outs together at a very early stage in the commercialisation process. In that way, we ensure new technologies meet real-world demands and needs. This agreement is yet another sign our approach is beginning to pay off."

 

 

Tarsis Technology and metal-organic frameworks:

 

Tarsis Technology specialises in developing metal-organic frameworks for the slower and more controlled delivery of active ingredients, such as agricultural chemicals. Metal-organic frameworks are particles combining organic and inorganic building blocks and are highly porous; they can adsorb a relatively large volume of an active ingredient compared to other types of particles.

 

The problem facing researchers in the past has been controlling the flow of the active ingredient from the particles - because they are porous, the ingredients leak out too quickly.

 

Tarsis Technology has developed a way of collapsing metal-organic frameworks (MOF) to lock an active ingredient inside the particle. There are many thousands of MOF particles, with different properties, including the rate at which they dissolve. Depending on which one is used, an active ingredient can be released over minutes, days or even months, or in response to climate or environmental changes.

 

 

 

 

 

 

 ENQUIRIES

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

andrew.johnson@frontierip.co.uk

Company website: www.frontierip.co.uk

 

M: 07464 546 025

Cenkos Securities plc (Nominated Adviser and Joint Broker)

T: 0131 220 6939

Neil McDonald / Beth McKiernan

 

Peterhouse Corporate Finance Limited (Joint Broker)

T: 020 7469 0935

Lucy Williams

 

Kreab (Financial PR)

T: 020 7074 1800

Robert Speed / Matthew Jervois

NOTES TO EDITORS

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services.

The Group looks to build and grow a portfolio of equity stakes and licence income from by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development. 

 

 

 

 

END

 

 

NRASSSFLMFASELL

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRABDGDRIDBBGIX
Date   Source Headline
30th Nov 20225:00 pmRNSTotal Voting Rights
25th Nov 20222:23 pmRNSDirector/PDMR Shareholding
23rd Nov 20225:17 pmRNSDirector share transfers
18th Nov 20223:53 pmRNSExercise of Options & PDMR Shareholdings
11th Nov 20223:07 pmRNSDirector/PDMR Dealing
11th Nov 20227:00 amRNSPosting of Annual Report and Notice of AGM
8th Nov 20227:00 amRNSPulsiv announces £1.5m fundraise
1st Nov 20221:46 pmEQSFrontier IP Group 'rigged for a storm' but confident of more progress
27th Oct 20227:00 amRNSFinal Results
19th Oct 20224:22 pmRNSHolding(s) in Company
19th Oct 20223:29 pmRNSHolding(s) in Company
14th Oct 20227:00 amRNSElute Intelligence appoints Steve Cable as CEO
27th Sep 20227:00 amRNSPulsiv unveils power electronics technology
18th Aug 20223:20 pmRNSSale of shares in Exscientia
5th Aug 20227:00 amRNSCamGraPhIC announces £1.26 million fundraising
26th Jul 20224:26 pmRNSHolding(s) in Company
26th Jul 20224:07 pmRNSHolding(s) in Company
24th May 20227:00 amRNSCambridge Raman Imaging raises £1.1 million
19th May 20227:00 amRNSPublication of newsletter
12th Apr 20225:18 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSUnaudited Half Year Results
14th Feb 20227:00 amRNSSale of shares in Exscientia
11th Feb 20225:04 pmRNSHolding(s) in Company
11th Feb 20222:05 pmRNSHolding(s) in Company
10th Feb 20227:00 amRNSCambridge Raman Imaging wins European Union grant
25th Jan 20227:00 amRNSSale of shares in Exscientia
17th Jan 20225:56 pmRNSHolding(s) in Company
12th Jan 20227:00 amRNSTrading update
11th Jan 20227:00 amRNSCelerum launch first commercial product
9th Dec 20212:33 pmRNSResult of AGM
29th Nov 20217:00 amRNSTVG - milestone in development of COVID-19 vaccine
9th Nov 20217:00 amRNSPosting of Annual Accounts and Notice of AGM
28th Oct 20217:00 amRNSDirectorate Change
28th Oct 20217:00 amRNSFinal Results
15th Oct 20217:00 amRNSPublication of newsletter
1st Oct 20217:59 amRNSPricing of IPO of Exscientia in the United States
30th Sep 20217:00 amRNSCamGraPhIC raises £1.6 million
27th Sep 20213:56 pmRNSUpdate on proposed IPO of Exscientia
24th Sep 20217:00 amRNSHolding(s) in Company
13th Sep 20217:00 amRNSExscientia - Statement filed for proposed IPO
8th Sep 20211:24 pmRNSExscientia enters $70M collaboration
8th Jul 20217:00 amRNSCamGraPhIC loan facility of up to £1.5 million
15th Jun 20217:00 amRNSPulsiv appoints Adam Westcott as CFO
14th Jun 20217:00 amRNSNandi Proteins appoints David Flower as CEO
11th Jun 20217:00 amRNSPublication of newsletter
24th May 20217:00 amRNSPulsiv complete £1.5m fundraising and appoints CEO
19th May 202111:53 amRNSExscientia collaboration with Bristol Myers Squibb
6th May 20217:00 amRNSThe Vaccine Group appoints Jeremy Salt as CEO
30th Apr 20211:58 pmRNSHolding(s) in Company
28th Apr 20217:01 amRNSTrading update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.